HUT51222A - Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient - Google Patents

Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient

Info

Publication number
HUT51222A
HUT51222A HU884575A HU457588A HUT51222A HU T51222 A HUT51222 A HU T51222A HU 884575 A HU884575 A HU 884575A HU 457588 A HU457588 A HU 457588A HU T51222 A HUT51222 A HU T51222A
Authority
HU
Hungary
Prior art keywords
halogen
producing
active ingredient
pharmaceutical compositions
prostaglandin derivatives
Prior art date
Application number
HU884575A
Other languages
English (en)
Other versions
HU206084B (en
Inventor
Bernd Buchmann
Werner Skuballa
Helmut Vorbrueggen
Bernd Raduechel
Olaf Loge
Walter Elger
Claus-Steffen Stuerzebecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25857817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT51222(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19873724189 external-priority patent/DE3724189A1/de
Priority claimed from DE19873724190 external-priority patent/DE3724190A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUT51222A publication Critical patent/HUT51222A/hu
Publication of HU206084B publication Critical patent/HU206084B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
HU884575A 1987-07-17 1988-07-15 Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient HU206084B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19873724189 DE3724189A1 (de) 1987-07-17 1987-07-17 9-halogen-(z)-(delta)(pfeil hoch)4(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel
DE19873724190 DE3724190A1 (de) 1987-07-17 1987-07-17 9-halogen-3-oxa-(z)-(delta)(pfeil hoch)5(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PCT/DE1988/000452 WO1989000559A1 (en) 1987-07-17 1988-07-15 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs

Publications (2)

Publication Number Publication Date
HUT51222A true HUT51222A (en) 1990-04-28
HU206084B HU206084B (en) 1992-08-28

Family

ID=25857817

Family Applications (1)

Application Number Title Priority Date Filing Date
HU884575A HU206084B (en) 1987-07-17 1988-07-15 Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient

Country Status (12)

Country Link
US (1) US6225347B1 (hu)
EP (1) EP0299914B2 (hu)
JP (1) JP2716986B2 (hu)
CA (1) CA1322197C (hu)
DE (1) DE3880034D1 (hu)
DK (1) DK170889B1 (hu)
ES (1) ES2054860T5 (hu)
HU (1) HU206084B (hu)
IE (1) IE62483B1 (hu)
IL (1) IL87116A (hu)
NZ (1) NZ225436A (hu)
WO (1) WO1989000559A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3923797A1 (de) * 1989-07-14 1991-01-24 Schering Ag 9-fluor-prostaglandin-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4008925A1 (de) * 1990-03-16 1991-09-19 Schering Ag 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4036140A1 (de) * 1990-11-09 1992-05-14 Schering Ag 9-halogen-11ss-hydroxy-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0652211A1 (en) * 1992-07-24 1995-05-10 Taisho Pharmaceutical Co. Ltd Prostaglandin derivative
DE4229050A1 (de) * 1992-08-31 1994-03-03 Schering Ag Neue 9-Chlor-Prostaglandin-Ester und -amide
DE4229048A1 (de) * 1992-08-31 1994-03-03 Schering Ag Ester von 9-Chlor-Prostaglandinen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
WO1994005631A1 (de) * 1992-08-31 1994-03-17 Schering Aktiengesellschaft 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
EP0666256A1 (en) * 1992-10-20 1995-08-09 Taisho Pharmaceutical Co. Ltd Prostaglandine derivative
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5627209A (en) * 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
WO1997018812A1 (en) * 1995-11-17 1997-05-29 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5700835A (en) * 1995-12-22 1997-12-23 Alcon Laboratories, Inc. 3-Oxa-D-prostaglandins for lowering IOP
US5599838A (en) * 1996-02-23 1997-02-04 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
CA2269853A1 (en) 1996-11-12 1998-05-22 Paul W. Zinke Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives
US6015922A (en) * 1997-12-19 2000-01-18 Alcon Laboratories, Inc. N-alkyl-N-alkoxycarboxamides and methods of use in prostaglandin synthesis
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
AU770867B2 (en) 1999-08-13 2004-03-04 Fumie Sato Prostaglandin derivatives
DE60043702D1 (de) * 1999-09-10 2010-03-04 Taisho Pharmaceutical Co Ltd Prostaglandin-derivate
GB0012249D0 (en) * 2000-05-19 2000-07-12 Chirotech Technology Ltd Process for the preparation of 11-oxaprostaglandins
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
AU2003254850B2 (en) * 2002-08-09 2008-05-15 Fumie Sato Antipruritic agent
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
WO2006014353A2 (en) 2004-07-02 2006-02-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
WO2007079078A1 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2350091B1 (en) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2544852C2 (ru) * 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MX2014012266A (es) 2012-04-12 2014-12-05 Xenon Pharmaceuticals Inc Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos.
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
AU2017371362A1 (en) 2016-12-09 2019-07-25 Celltaxis, Llc Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase
CA3045950A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2018107158A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754114A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux composes de la classe des prostaglandines et leur procede de preparation
US3936487A (en) 1970-06-17 1976-02-03 The Upjohn Company 3-Oxa prostaglandin Fα-type compounds
US3954835A (en) 1972-04-27 1976-05-04 The Upjohn Company 4,5-Cis-didehydro-PGF1 compounds
US3980694A (en) 1974-04-11 1976-09-14 The Upjohn Company 4-Oxa phenyl-substituted PGA compounds
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE2950027A1 (de) * 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
DE3048906A1 (de) 1980-12-19 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3126924A1 (de) 1981-07-03 1983-01-20 Schering Ag, 1000 Berlin Und 4619 Bergkamen 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4971987A (en) * 1984-07-27 1990-11-20 Schering Aktiengesellschaft New carbacycline, process for their production and their use as a drug
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0652211A1 (en) 1992-07-24 1995-05-10 Taisho Pharmaceutical Co. Ltd Prostaglandin derivative

Also Published As

Publication number Publication date
ES2054860T5 (es) 2003-11-01
EP0299914B1 (de) 1993-04-07
EP0299914A1 (de) 1989-01-18
IL87116A (en) 1993-03-15
US6225347B1 (en) 2001-05-01
HU206084B (en) 1992-08-28
IE62483B1 (en) 1995-02-08
NZ225436A (en) 1991-04-26
DE3880034D1 (de) 1993-05-13
DK170889B1 (da) 1996-03-04
WO1989000559A1 (en) 1989-01-26
ES2054860T3 (es) 1994-08-16
JPH02502009A (ja) 1990-07-05
EP0299914B2 (de) 2003-04-23
IL87116A0 (en) 1988-12-30
JP2716986B2 (ja) 1998-02-18
CA1322197C (en) 1993-09-14
DK132789A (da) 1989-03-17
IE882189L (en) 1989-01-17
DK132789D0 (da) 1989-03-17

Similar Documents

Publication Publication Date Title
HUT51222A (en) Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
HUT47131A (en) Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient
HUT52089A (en) Process for producing triazole derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT56270A (en) Process for producing taxol derivatives and pharmaceutical compositions comprising such active ingredient
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HUT49625A (en) Process for producing macrolid compounds and pharmaceutical compositions comprising such active ingredient
HUT47552A (en) Process for producing 10-dihydro-10-deoxo-11-aza-erythronolid a derivatives and pharmaceutical compositions containing them as active components
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
HUT58060A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
HUT48247A (en) Process for producing aza-bicyclo-octyl-ether derivatives and pharmaceutical compositions containing them as active components
HUT52093A (en) Process for producing indazole-3-carboxylic acid derivatives and pharmaceutical compositions comprising same
HUT48269A (en) Process for producing pharmaceutically active nukleozide and pharmaceutical compositions containing them
HUT49367A (en) Process for producing aristeromycin/adenosine derivatives and pharmaceutical compositions comprising same as active ingredient
HUT53897A (en) Process for producing benzopyran derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT48870A (en) Process for producing aminoalkoxyphenyl derivatives and pharmaceutical compositions comprising same
HUT54671A (en) Process for producing benzothiopirane derivatives and pharmaceutical compositions containing them as active component
HUT48251A (en) Process for producing new xantin derivatives and pharmaceutical compositions containing them as active components
HUT55394A (en) Process for producing pirrolidino-piperazine-dion derivatives and pharmaceutical compositions containing them as active components
HUT49598A (en) Process for producing chromone derivatives and pharmaceutical compositions comprising same as active ingredient
HUT49370A (en) Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient
HUT58082A (en) Process for producing chroman derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT59116A (en) Process for producing oxazole derivatives and pharmaceutical compositions comprising oxazole derivatives as active ingredient
HUT47210A (en) Insecticide compositions and process for producing benzoyl-urea derivatives as active components

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees